📊 DOCEBO INC. (DCBO)
EARNINGS REPORT CARD – Q2 & 6-MONTH FY2026
📅 Quarter Ended: June 30, 2026 (Q2) | Six Months Ended: June 30, 2026 (6M)📄 Source: Company Reports, MD&A, Earnings Call Transcript
🏆 VERDICTS & CSI CARD
- CSI SCORE: 7.7 / 10 🟢 (GOOD / IMPROVING)
- Q2 FY2026 VERDICT: 🟢 STRONG. Revenue beat estimates, management raised guidance, ARR re-accelerated, strong Adjusted EBITDA. GAAP net income dropped YoY but underlying business operations improved.
- 6-MONTH FY2026 VERDICT: 🟢 IMPROVING. Steady double-digit revenue growth. Enterprise execution is strong despite tough software macro environment. Leverage on balance sheet is present but manageable.
🏢 COMPANY OVERVIEW
📈 FINANCIAL RESULTS (Simulated Two-Column Layout)
| Metric | Q2 FY2026 | Q2 FY2025 | Change | Change (%) | 6M FY2026 (YTD) | 6M FY2025 (Est.) | Change (%) | |
| 💵 Revenue | $68.65M | $60.73M | +$7.92M | 🟢 +13.0% | $134.25M | $117.70M | 🟢 +14.0% | |
| 💰 Gross Profit | $54.53M | $49.15M | +$5.38M | 🟢 +11.0% | ~$107.40M | ~$94.16M | 🟢 +14.0% | |
| 📊 Gross Margin | 79.4% | 80.9% | -1.5 pts | 🟡 -150 bps | ~80.0% | ~80.0% | 🟡 Flat | |
| ⚙️ Operating Exp. | $50.39M | $48.06M | +$2.33M | 🟡 +4.8% | ~$101.55M | ~$93.07M | 🟡 +9.1% | |
| 📈 Op. Income | $4.14M | $1.09M | +$3.05M | 🟢 +279% | $5.85M | N/A | 🟢 N/A | |
| 📉 Net Income | $2.26M | $3.08M | -$0.82M | 🟡 -26.6% | $4.55M | N/A | 🟡 N/A | |
| 👤 EPS (Diluted) | $0.08 | $0.10 | -$0.02 | 🟡 -20.0% | $0.15 | N/A | 🟡 N/A |
📸 KEY SNAPSHOT (As of June 30, 2026)
| Metric | Value | Notes |
| 💵 Cash & Equivalents | $45.70M | Manageable liquidity position. |
| ⏱️ Working Capital | -$30.21M | Negative working capital dynamic. |
| 💳 Total Debt | $88.00M | Net debt sits at approx. $42.3M. |
| 👥 Shares Out. (Diluted) | 26.80M | vs. 25.46M Basic (approx. 1.34M option/RSU overhang). |
⚖️ STRENGTHS & RISKS
- Guidance Raise: Raised full-year revenue guidance by $3.5M and held Adjusted EBITDA guidance steady ($54.5M - $56.5M).
- Enterprise Acceleration: Strong win rates and pipeline in Enterprise accounts drove outperformance.
- Margin Expansion: Adjusted EBITDA margin improved to 16.4% ($11.23M) from 15.2% ($9.22M) a year ago.
- AI Product Pipeline: Agent Hub and Enterprise Knowledge are launching in early Fall 2026.
- GAAP Profitability Drop: GAAP Net Income and EPS fell YoY due to higher non-operating or tax expenses, despite operating income tripling.
- Negative Operating Cash Flow: Q2 Cash Provided by Operating Activities was -$3.07M.
- Leveraged Balance Sheet: Total borrowings ($88M) exceed cash reserves ($45.7M).
- Working Capital Deficit: Reported a working capital deficit of $30.2M for the quarter.
🎯 KEY TAKEAWAY
Docebo delivered a robust Q2 FY2026, punctuated by a double-beat on the top and bottom lines and a subsequent guidance raise. While GAAP net income dipped and working capital remains negative, the core underlying business is accelerating. Enterprise pipeline execution is strong, and management's focus on specialized verticals (Healthcare) and upcoming AI integrations (Agent Hub) positions the company well for sustained recurring revenue growth.
🧮 CSI SCORECARD (0 = Weak, 10 = Strong)
- 💼 Earnings Quality: 7.5 (Improving)
- 🛡️ Balance Sheet Risk: 6.5 (Mixed - Due to $88M Debt vs $45.7M Cash)
- 💧 Dilution Risk: 8.5 (Low - Manageable 5% overhang)
- 🗣️ Management Credibility: 8.5 (Strong - Conservative guidance, consistent beats)
- 🌟 Confidence Level: 8.0 (Strong - Enterprise traction and ARR acceleration)
🔮 SCENARIO OUTLOOK (FY2026)
| 🟢 BULL CASE (25%) | 🟡 BASE CASE (50%) | 🔴 BEAR CASE (25%) |
| Revenue: $278M+ | Revenue: $274.5M - $276.5M | Revenue: $270M |
| Adj. EBITDA: $58M+ | Adj. EBITDA: $54.5M - $56.5M | Adj. EBITDA: $52M |
| Accelerated adoption of Agent Hub; rapid ROI from Healthcare vertical expansion; robust FCF generation. | Meets management guidance; steady conversion of enterprise pipeline; predictable ARR growth. | Macro headwinds stall enterprise sales cycles; healthcare investments drag on margins; cash burn persists. |
Werbung - Meine Toolbox InvestingPro
https://www.investing-referral.com/aff239/
„Spekulative Investments sind wie ein Tennismatch: Entscheidend ist die volle Konzentration auf das nächste As, anstatt sich über den letzten Doppelfehler zu ärgern.“ A. Gerstenberger
::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::
Disclaimer / Haftungsausschluss
Dieser Text wurde teilweise mit KI Anwendungen erstellt.
Alle Inhalte dienen nur zur Information und stellen keine Anlageberatung oder Aufforderung zum Kauf oder Verkauf von Wertpapieren oder anderen Finanzmarktinstrumenten dar. Selbstverständlich bemühe ich mich, die Fakten nach bestem Wissen und Gewissen zu präsentieren, aber sie können trotzdem ganz oder teilweise falsch sein.
Daher gilt: Ich übernehme keinerlei Haftung für Anlageentscheidungen, die Sie aufgrund der hier präsentierten Informationen treffen.
Interessenkonflikt: Der Autor dieser Publikation hält zum Zeitpunkt der Veröffentlichung Aktien/Wertpapiere der hier besprochenen Werte/Unternehmen und hat die Absicht, diese je nach Marktsituation zu veräußern und könnte dabei insbesondere von erhöhter Handelsliquidität profitieren. Hierdurch besteht konkret und eindeutig ein Interessenkonflikt.